Research Article
Poststroke Hip Fracture: Prevalence, Clinical Characteristics, Mineral-Bone Metabolism, Outcomes, and Gaps in Prevention
Table 5
Clinical and laboratory characteristics independently associated with poststroke hip fracture.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
OR: odds ratio; CI: confidence interval; TIA: transient ischaemic attack; CAD: coronary artery disease; VIF: variance inflation factor. Model 1 (clinical parameters) adjusts for age, sex, dementia, hypertension, CAD, history of myocardial infarction, TIA: atrial fibrillation, renal impairment (eGFR < 60 mL/min/1.73 m2), use of walking aid, and living in a long-term residential care facility. Model 2 (laboratory parameters) adjusts for age, sex, vitamin D insufficiency (25(OH)D < 50 nmol/L), elevated PTH (>6.8 pmol/L), and high bone resorption markers (DPD/Cr > 7.5 mmol/mol, NTX/Cr > 65 mmol/mol). Model 3 (combined clinical and laboratory parameters) adjusts for al variables in Models 1 and 2. |